Top ۱۰۰ Most Cited Publications on CTLA-۴ Molecule in Cancer Research: A Bibliometric Analysis

سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 102

فایل این مقاله در 16 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_MISJ-14-1_001

تاریخ نمایه سازی: 25 آبان 1402

چکیده مقاله:

The aim of this research is to use bibliometric analysis to investigate the status and patterns of the ۱۰۰ most frequently cited publications regarding the cytotoxic Tlymphocyte- associated protein (CTLA-۴) research for cancer. The articles published on the topic were retrieved from the core collection database of Web of Science and PubMed using the Medical Subject Heading (MeSH) of “CTLA-۴” from ۱۹۸۶ to December ۶, ۲۰۲۰. The selected articles were examined and the bibliometric data compiled based on the number of citations, the author’s name, journal, publication year, institution, country, and co-occurrence keywords. ۴,۸۷۴ eligible papers were returned from the Web of Science Core Collection Database and PubMed. The citation frequency ranged from ۲۳۷۲ to ۲۰۵, with a median of ۴۶۰, and the top cited paper had ۲۳۷۲ citations. The journals with the most papers were Cell (n = ۸, ۳۵۴۱ citations, Impact Factor (IF) = ۴۱.۵۷۷) and Journal of Experimental Medicine (n = ۷, ۲۷۱۶ citations, IF = ۱۰.۷۹۰). Most of the published papers were from the United States of America (USA) (۴۱.۸%). A total of ۴۸۵ institutes and ۲۹ countries were involved in these ۱۰۰ articles. There were ۱۱۹۲ authors and the author with the highest number of papers was the Nobel Prize winner, Professor James P. Allison (۱۷ papers; ۸۷۰۰ citations). CTLA-۴ blockade was the most frequent keyword (۴۲.۱%), followed by metastatic melanoma (۴.۲۶%). This work presents an important bibliographic source and can be saved as a reference for future medical health research on the function of CTLA-۴ in cancer immunotherapy.

کلیدواژه ها:

bibliometric analysis ، CTLA-۴ Protein ، Cytotoxic T-Lymphocyte Antigen ۴ ، cancer ، immunotherapy

نویسندگان

Hossam El Idrissi

Faculty of Medicine and Pharmacy of Casablanca, University of Hassan ۲, Casablanca, Morocco

Ibtissam Balar

Neuropsychology Department, University of Paris ۸, Vincennes-Saint-Denis, Paris, France

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, ...
  • Ichim CV. Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. ...
  • Burnet M. Cancer; a biological approach. I. The processes of ...
  • Zang X. ۲۰۱۸ Nobel Prize in medicine awarded to cancer ...
  • Huang PW, Chang JW. Immune checkpoint inhibitors win the ۲۰۱۸ ...
  • Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, ...
  • Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, ...
  • Olive D, le Thi S, Xerri L, Hirsch I, Nunès ...
  • Krummel MF, Allison JP. CD۲۸ and CTLA-۴ have opposing effects ...
  • Mansh M. Ipilimumab and cancer immunotherapy: a new hope for ...
  • Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, ...
  • MeSH Databases. [Internet] NCBI Home MeSH (۲۰۲۰). [cited on: ۰۶ ...
  • Journal Citation Reports. [Internet] Clarivate Analytics (۲۰۱۸). [cited on: ۲۷ ...
  • Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer ...
  • Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, ...
  • Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in ...
  • Petrelli F, De Stefani A, Trevisan F, Parati C, Inno ...
  • Kotlowska MP, Rueda AG, Olmedo ME, Benito A, Roldán AS, ...
  • Bates JE, Morris CG, Milano MT, Yeung AR, Hoppe BS. ...
  • Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and ...
  • Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, ...
  • Gao Y, Shi S, Ma W, Chen J, Cai Y, ...
  • Zhao X, He L, Mao K, Chen D, Jiang H, ...
  • Zhong Q, Li BH, Zhu QQ, Zhang ZM, Zou ZH, ...
  • Baş Y, Şenel E. A Holistic evaluation of articles on ...
  • Gilman NV. Analysis for science librarians of the ۲۰۱۸ nobel ...
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. ...
  • World economic situation and prospects ۲۰۲۰. [Internet] Department of Economic ...
  • Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, ...
  • Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, ...
  • Sharma P, Allison JP. The future of immune checkpoint therapy. ...
  • O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, ...
  • Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a ...
  • Peng W, Chen JQ, Liu C, Malu S, Creasy C, ...
  • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, ...
  • Chen Q, Xu L, Liang C, Wang C, Peng R, ...
  • Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, ...
  • Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer ...
  • Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, ...
  • Curran MA, Montalvo W, Yagita H, Allison JP. PD-۱ and ...
  • Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. ...
  • McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, ...
  • Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, ...
  • Van Allen EM, Miao D, Schilling B, Shukla SA, Blank ...
  • Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu; Cancer Genome ...
  • Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, ...
  • Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, ...
  • Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, ...
  • Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, ...
  • Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: ...
  • Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. ...
  • Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, ...
  • Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia ...
  • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse ...
  • Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future ...
  • Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents ...
  • Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. ...
  • Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers ...
  • Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, ...
  • Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, ...
  • Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint ...
  • Chen DS, Mellman I. Elements of cancer immunity and the ...
  • Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer ...
  • Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, ...
  • Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning ...
  • Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, ...
  • BCarthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang ...
  • Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, ...
  • Boussiotis VA. Molecular and biochemical aspects of the PD-۱ checkpoint ...
  • Tirosh I, Izar B, Prakadan SM, Wadsworth MH ۲nd, Treacy ...
  • J Gao J, Shi LZ, Zhao H, Chen J, Xiong ...
  • Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, ...
  • Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, ...
  • Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, ...
  • Le DT, Lutz E, Uram JN, Sugar EA, Onners B, ...
  • Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, ...
  • Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, ...
  • Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, ...
  • Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, ...
  • Myers G. Immune-related adverse events of immune checkpoint inhibitors: a ...
  • Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng ...
  • Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, ...
  • Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. ...
  • Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, ...
  • Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, ...
  • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. ...
  • Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, ...
  • Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, ...
  • Fedorov VD, Themeli M, Sadelain M. PD-۱- and CTLA-۴-based inhibitory ...
  • Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, ...
  • Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. ...
  • Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. ...
  • Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, ...
  • Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, ...
  • Royal RE, Levy C, Turner K, Mathur A, Hughes M, ...
  • Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. ...
  • Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, ...
  • Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. ۲۰۱۶;۱۶۴(۶):۱۲۳۳-۴۷. ...
  • Chen L, Han X. Anti-PD-۱/PD-L۱ therapy of human cancer: past, ...
  • Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, ...
  • Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, ...
  • Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, ...
  • Buchbinder EI, Desai A. CTLA-۴ and PD-۱ pathways: Similarities, differences, ...
  • van den Eertwegh AJ, Versluis J, van den Berg HP, ...
  • Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, ...
  • Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, ...
  • Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. ...
  • Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, ...
  • Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, ...
  • Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, ...
  • Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. ...
  • Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, ...
  • Postow MA, Sidlow R, Hellmann MD. Immunerelated adverse events associated ...
  • Weber JS, Dummer R, de Pril V, Lebbé C, Hodi ...
  • Weber J, Thompson JA, Hamid O, Minor D, Amin A, ...
  • Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: ...
  • Ott PA, Hodi FS, Robert C. CTLA-۴ and PD-۱/PDL۱ blockade: ...
  • Kim K, Skora AD, Li Z, Liu Q, Tam AJ, ...
  • Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV۶۰۰E: implications for carcinogenesis ...
  • Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, ...
  • Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, ...
  • Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related ...
  • Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, ...
  • Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, ...
  • نمایش کامل مراجع